Abstract
ALL in which the Philadelphia (Ph) chromosome is detected is one of the few diseases in which there is almost unequivocal agreement that a matched sibling allogeneic haematopoietic stem cell transplant in first CR is the most appropriate therapy for patients within certain age limits. Extension of allogeneic stem cell transplant to patients without matched sibling donors or to older individuals is increasingly possible due to unrelated donors, umbilical cord blood and reduced-intensity conditioning regimens. Here, we carefully review evidence supporting current practice and examine recent evidence relating to the use of newer allogeneic transplant technologies in Ph-pos ALL. We explore the burgeoning literature on the role of tyrosine kinase inhibitors in this disease and summarize their impact on the transplant practice.
| Original language | English |
|---|---|
| Pages (from-to) | 447-53 |
| Number of pages | 7 |
| Journal | Bone marrow transplantation |
| Volume | 41 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Mar 2008 |
Keywords
- Disease-Free Survival
- Graft vs Leukemia Effect
- Hematopoietic Stem Cell Transplantation/methods
- Humans
- Myeloablative Agonists/therapeutic use
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Protein Kinase Inhibitors/therapeutic use
- Transplantation Conditioning/methods
- Transplantation, Homologous/methods